Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

SWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Southwest Oncology Group
ClinicalTrials.gov Identifier:
NCT01000558
First received: October 22, 2009
Last updated: May 17, 2013
Last verified: May 2013

October 22, 2009
May 17, 2013
March 2005
July 2011   (final data collection date for primary outcome measure)
Establishment of a Centralized Lymphoma Serum Repository for the Southwest Oncology Group [ Time Frame: July 2011 ] [ Designated as safety issue: No ]
  • Establishment of a Centralized Lymphoma Serum Repository for the Southwest Oncology Group [ Designated as safety issue: No ]
  • Provide a unique database resource for clinicopathologic correlations with the results of any serum assay [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01000558 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
SWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol

RATIONALE: Collecting and storing samples of blood from patients with cancer to test in the laboratory may help the study of cancer in the future.

PURPOSE: This research study is collecting and storing blood samples from patients with previously untreated non-Hodgkin lymphoma.

OBJECTIVES:

  • To establish a central lymphoma serum repository that will serve as a resource to provide specimens for current and future scientific studies.
  • To utilize the Southwest Oncology Group clinical database to perform clinicopathologic correlations with the results of those studies.

OUTLINE: Serum is collected and stored for future correlative studies.

Observational
Not Provided
Not Provided
Retention:   Samples With DNA
Description:

blood and serum for patients consenting to banking on lymphoma treatment studies

Non-Probability Sample

Patients consenting to 8947 banking of blood and serum

Lymphoma
Other: biologic sample preservation procedure
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
939
July 2011
July 2011   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Diagnosis of non-Hodgkin lymphoma

    • Previously untreated disease
    • Patients must meet the eligibility criteria and be registered to a currently active Southwest Oncology Group-coordinated treatment protocol for previously untreated non-Hodgkin lymphoma

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01000558
CDR0000390329, SWOG-8947, U10CA032102
No
Southwest Oncology Group
Southwest Oncology Group
National Cancer Institute (NCI)
Study Chair: Richard I. Fisher, MD James P. Wilmot Cancer Center
Southwest Oncology Group
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP